MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial

MAIA recently announced that it has completed international enrollment in Part C of the Phase 2 THIO-101 expansion trial. Treatment with ateganosine followed by cemiplimab has shown an acceptable ...

Financing the Space Economy at America’s 250th: American DeepTech Applauds “Moonfra” Financing; the Birth of US Sovereign Grade Space Leverage

Firm highlights White House, SBA, NASA and Bipartisan Congress for their support for Lunar Infrastructure and US Space Economy Leadership WASHINGTON, D.C. / ACCESS Newswire / July 2, 2026 / As the ...